FY2026 Earnings Forecast for LSTA Issued By HC Wainwright

Lisata Therapeutics, Inc. (NASDAQ:LSTA) – Research analysts at HC Wainwright issued their FY2026 EPS estimates for shares of Lisata Therapeutics in a note issued to investors on Friday, May 15th. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($1.09) per share for the year. HC Wainwright has a “Neutral” rating on the stock.

Several other research firms have also recently commented on LSTA. cut shares of Lisata Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lisata Therapeutics in a research report on Tuesday, April 21st. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Reduce” and an average price target of $15.00.

Lisata Therapeutics Trading Down 1.6%

NASDAQ:LSTA opened at $3.12 on Tuesday. The company has a 50-day moving average price of $4.21 and a 200-day moving average price of $3.37. Lisata Therapeutics has a 12 month low of $1.81 and a 12 month high of $5.07. The stock has a market cap of $28.41 million, a price-to-earnings ratio of -1.68 and a beta of 0.81.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.50) earnings per share for the quarter.

Institutional Investors Weigh In On Lisata Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC increased its stake in shares of Lisata Therapeutics by 6.5% in the 1st quarter. Renaissance Technologies LLC now owns 131,715 shares of the company’s stock worth $660,000 after acquiring an additional 8,000 shares in the last quarter. Deltec Asset Management LLC bought a new position in shares of Lisata Therapeutics in the 1st quarter worth about $451,000. Rangeley Capital LLC bought a new position in shares of Lisata Therapeutics in the 1st quarter worth about $376,000. Ground Swell Capital LLC increased its stake in shares of Lisata Therapeutics by 64.0% in the 4th quarter. Ground Swell Capital LLC now owns 38,987 shares of the company’s stock worth $73,000 after acquiring an additional 15,213 shares in the last quarter. Finally, CIBC Bancorp USA Inc. bought a new position in shares of Lisata Therapeutics in the 3rd quarter worth about $37,000. 8.94% of the stock is owned by hedge funds and other institutional investors.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.